Richard B. Brewer

Richard Brooke Brewer (April 6, 1951 – August 15, 2012) was a biotechnology and pharmaceutical industry executive. At the time of his death in 2012, he was president and chief executive officer of Myrexis, which he had joined in May 2012.^{[citation needed]}

Education[]

Brewer received a bachelor of science from Virginia Tech in 1974 and an MBA from Northwestern University in 1984.^[2][4]

Career[]

From 1984 to 1995, Brewer was the senior vice president of sales and marketing and later the senior vice president of Genentech Europe and Canada.^[4] Brewer was then the Chief Operating Officer of from 1996 to 1998.

In 1998, he became the president and Chief Executive Officer of , a position he held until 2004. In 2001, he was diagnosed with multiple myeloma, a form of blood cancer.^[2] He was the managing partner of from 2003 to 2009.^[4]

In his career, Brewer guided development and commercialization of breakthrough drugs including human growth hormone for children's growth disorders; the first new drug in 30 years for cystic fibrosis; the first new drug in over a decade for heart failure; clot-busting drugs for heart attacks and strokes; and other drugs and devices for cancer and heart disease.^[3]

He served on the board of directors of several companies, including SRI International. At the time of his death, he was chairman of the board of and , and was executive chairman of .^[4]

References[]